Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

(2022) Hung Fu Tseng et al.   NATURE MEDICINE

Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar

(2022) Laith J. Abu-Raddad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar

(2022) Laith J. Abu-Raddad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection

(2022) Heba N. Altarawneh et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity

(2022) Stefan Pilz et al.   ENVIRONMENTAL RESEARCH

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

(2022) Nick Andrews et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar

(2022) Laith J. Abu-Raddad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar

(2022) Hiam Chemaitelly et al.   Nature Communications

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

(2021) Robert Challen et al.   BMJ-British Medical Journal

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

(2021) Laith J. Abu-Raddad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic

(2021) Laith J. Abu-Raddad et al.   Scientific Reports

SARS-CoV-2 infection is at herd immunity in the majority segment of the population of Qatar

(2021) Mohamed H Al-Thani et al.   Open Forum Infectious Diseases

Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses

(2021) Laith J Abu-Raddad et al.   JOURNAL OF TRAVEL MEDICINE

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

(2021) Hiam Chemaitelly et al.   NATURE MEDICINE

SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals

(2021) Peter V. Coyle et al.   iScience

Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant

(2021) Hiam Chemaitelly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

(2021) Hiam Chemaitelly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study

(2021) Laith J. Abu-Raddad et al.   PLOS MEDICINE

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls

(2017) Jennifer R. Verani et al.   VACCINE

The test-negative design for estimating influenza vaccine effectiveness

(2013) Michael L. Jackson et al.   VACCINE

Is it necessary to adjust for calendar time in a test negative design?

(2013) Peter Jacoby et al.   VACCINE

Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research

(2009) Peter C. Austin   COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION